[
  {
    "ts": "2026-02-03T00:28:59+00:00",
    "headline": "Bristol-Myers Squibb Company (BMY): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Bristol-Myers Squibb Company on Disruptive Analytics’ Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on BMY. Bristol-Myers Squibb Company’s share was trading at $55.05 as of January 30th. BMY’s trailing and forward P/E were 18.28 and 9.09, respectively according to Yahoo Finance. Bristol-Myers Squibb Company discovers, develops, […]",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-002859308.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "45fd6b8a-2e46-3fab-b47d-30c91ea0f4a0",
      "content": {
        "id": "45fd6b8a-2e46-3fab-b47d-30c91ea0f4a0",
        "contentType": "STORY",
        "title": "Bristol-Myers Squibb Company (BMY): A Bull Case Theory",
        "description": "",
        "summary": "We came across a bullish thesis on Bristol-Myers Squibb Company on Disruptive Analytics’ Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on BMY. Bristol-Myers Squibb Company’s share was trading at $55.05 as of January 30th. BMY’s trailing and forward P/E were 18.28 and 9.09, respectively according to Yahoo Finance. Bristol-Myers Squibb Company discovers, develops, […]",
        "pubDate": "2026-02-03T00:28:59Z",
        "displayTime": "2026-02-03T00:28:59Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/87c52b6250133265982f3f09a85b29c6",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "Why Impact Biomedical Inc. (IBO) Surged On Thursday?",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fIdT9.k205RuBbbwuNwv4w--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/87c52b6250133265982f3f09a85b29c6.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1CFt_BfS6SqlkTGuw5_Dyw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/87c52b6250133265982f3f09a85b29c6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-002859308.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-002859308.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-03T10:12:07+00:00",
    "headline": "Bristol-Myers Squibb (BMY) Poised for Upside With Registrational Data Ahead",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) ranks among the stocks with the lowest forward PE ratios. Leerink Partners boosted its price target for Bristol-Myers Squibb Company (NYSE:BMY) to $60 from $54 on January 13, maintaining an Outperform rating on the company’s shares. The firm cited substantial pipeline flexibility in 2026 as the key justification for the higher […]",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-bmy-poised-101207522.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "ee25bde4-3217-3eea-9691-493331182747",
      "content": {
        "id": "ee25bde4-3217-3eea-9691-493331182747",
        "contentType": "STORY",
        "title": "Bristol-Myers Squibb (BMY) Poised for Upside With Registrational Data Ahead",
        "description": "",
        "summary": "Bristol-Myers Squibb Company (NYSE:BMY) ranks among the stocks with the lowest forward PE ratios. Leerink Partners boosted its price target for Bristol-Myers Squibb Company (NYSE:BMY) to $60 from $54 on January 13, maintaining an Outperform rating on the company’s shares. The firm cited substantial pipeline flexibility in 2026 as the key justification for the higher […]",
        "pubDate": "2026-02-03T10:12:07Z",
        "displayTime": "2026-02-03T10:12:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/52c9c784bf549608e91c2900af16ebed",
          "originalWidth": 158,
          "originalHeight": 128,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vDyP7pqW3TbUTzh67tIgVg--~B/aD0xMjg7dz0xNTg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/52c9c784bf549608e91c2900af16ebed.cf.webp",
              "width": 158,
              "height": 128,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/X8b4DTWv677oFnBOijPswg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/52c9c784bf549608e91c2900af16ebed.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-bmy-poised-101207522.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-bmy-poised-101207522.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-03T11:59:00+00:00",
    "headline": "Bristol Myers Squibb Introduces \"Change the Target. Change What’s Possible.\" to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care",
    "summary": "PRINCETON, N.J., February 03, 2026--Bristol Myers Squibb Introduces \"Change the Target. Change What’s Possible.\" to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-introduces-change-115900219.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "7329ff0e-7f73-3aa8-b7cd-e1cd99f850dc",
      "content": {
        "id": "7329ff0e-7f73-3aa8-b7cd-e1cd99f850dc",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb Introduces \"Change the Target. Change What’s Possible.\" to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care",
        "description": "",
        "summary": "PRINCETON, N.J., February 03, 2026--Bristol Myers Squibb Introduces \"Change the Target. Change What’s Possible.\" to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care",
        "pubDate": "2026-02-03T11:59:00Z",
        "displayTime": "2026-02-03T11:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/facdbec908ef0d232f2abce37c9da87e",
          "originalWidth": 1497,
          "originalHeight": 206,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kZJzRGmsRkiNRUO8k0yWYg--~B/aD0yMDY7dz0xNDk3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/facdbec908ef0d232f2abce37c9da87e.cf.webp",
              "width": 1497,
              "height": 206,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vGFrNCFSq7crKUwNRODMQg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/facdbec908ef0d232f2abce37c9da87e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-introduces-change-115900219.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-introduces-change-115900219.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-03T16:39:00+00:00",
    "headline": "Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?",
    "summary": "BMY leans on fast-growing Reblozyl, now a $2B+ franchise, to fuel results as generics pressure legacy drugs ahead of Q4 earnings.",
    "url": "https://finance.yahoo.com/news/reblozyl-shine-bristol-myers-fourth-163900670.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "15690c5f-3f2b-3b77-a242-9e477de833f9",
      "content": {
        "id": "15690c5f-3f2b-3b77-a242-9e477de833f9",
        "contentType": "STORY",
        "title": "Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?",
        "description": "",
        "summary": "BMY leans on fast-growing Reblozyl, now a $2B+ franchise, to fuel results as generics pressure legacy drugs ahead of Q4 earnings.",
        "pubDate": "2026-02-03T16:39:00Z",
        "displayTime": "2026-02-03T16:39:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AZ1NFKr1Arip4UWINeWStw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zL5_evNVQm1N5N.bc6WldQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/reblozyl-shine-bristol-myers-fourth-163900670.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/reblozyl-shine-bristol-myers-fourth-163900670.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]